01.12.2021 15:29

Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome

Folgen
Werbung
Fresenius Medical Care AG & Co. FMS recently announced that it is launching a new dialyzer for hemodialysis, the FX CorAL— the newest dialyzer in the company’s FX class of dialyzers which use polysulfone (a special plastic with exceptional filtering and hemocompatibility characteristics). The FX CorAL was unveiled in Fresenius Medical Care’s NephroCare clinics after it received the CE mark, and has already been used in more than three million treatments.For investors’ note, the FX CorAL is already available in Switzerland and will be gradually launched in Germany, France, Italy and the United Arab Emirates. Other countries in the company’s Europe, Middle East and Africa region will follow.The latest launch is expected to significantly solidify Fresenius Medical’s business on a global scale.Significance of the LaunchThe highlight of the FX CorAL dialyzer is its clinical performance and hemocompatibility. It is noteworthy to mention that dialysis patients often suffer from chronic inflammation caused by the accumulation of toxic substances and the regular contact of their blood with external substances. These inflammations reduce patients’ quality of life and lead to the onset of cardiovascular diseases.The design of the FX CorAL dialyzer is such that it absorbs lower proteins, thereby achieving a lower induction of the immune response in the patient while maintaining high selective permeability for the removal of toxins and excess water. Additionally, all FX-class dialyzers are steam-sterilized and environment friendly.Per management, combining clinical performance with hemocompatibility is expected to significantly improve treatment quality of the company’s dialysis patients, thereby enhancing the patients’ well-being.Industry ProspectsPer a report published by Market Reports World, the global dialyzer market was valued at $6535 million in 2020 and is expected to reach $10210 million by the end of 2027 at a CAGR of 6.6%. Factors like rise in elderly population and surge in incidence of renal diseases (especially end stage renal disease) are likely to drive the market.Given the market potential, the latest launch is expected to significantly boost Fresenius Medical’s business on a global scale.Notable DevelopmentIn November, Fresenius Medical announced its third-quarter 2021 financial results, where it registered revenue growth across EMEA, Asia Pacific and Latin America regions.Price PerformanceShares of the company have lost 29.2% in the past year against the industry’s 8.2% rise and the S&P 500 composite’s 27.6% growth.Image Source: Zacks Investment ResearchZacks Rank & Stocks to ConsiderCurrently, Fresenius Medical carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation ABC, Thermo Fisher Scientific Inc. TMO and AMN Healthcare Services AMN.AmerisourceBergen, carrying a Zacks Rank #2 (Buy), reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.39, which beat the Zacks Consensus Estimate by 1.3%. Revenues of $58.91 billion outpaced the consensus mark by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.AmerisourceBergen has an estimated long-term growth rate of 11.3%. The company surpassed estimates in the trailing four quarters, the average surprise being 5.48%.Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.Zacks Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Fresenius SE & Co. KGaA (St.)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Fresenius SE & Co. KGaA (St.)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
17.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
11.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
04.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
01.12.2021Fresenius SECo HoldDeutsche Bank AG
22.11.2021Fresenius SECo HoldJefferies & Company Inc.
11.11.2021Fresenius SECo KaufenDZ BANK
02.11.2021Fresenius SECo KaufenNorddeutsche Landesbank (Nord/LB)
02.11.2021Fresenius SECo BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.11.2021Fresenius SECo OverweightBarclays Capital
02.11.2021Fresenius SECo BuyGoldman Sachs Group Inc.
17.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
11.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
04.01.2022Fresenius SECo NeutralJP Morgan Chase & Co.
01.12.2021Fresenius SECo HoldDeutsche Bank AG
22.11.2021Fresenius SECo HoldJefferies & Company Inc.
02.11.2021Fresenius SECo UnderperformJefferies & Company Inc.
30.07.2021Fresenius SECo UnderperformJefferies & Company Inc.
23.07.2021Fresenius SECo UnderperformJefferies & Company Inc.
17.03.2021Fresenius SECo UnderperformJefferies & Company Inc.
23.02.2021Fresenius SECo UnderperformJefferies & Company Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius SE & Co. KGaA (St.) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX gibt deutlich nach -- Accell von KKR übernommen -- Infineon sieht 2023 Ende der Chipkrise -- Evergrande, Lufthansa, Commerzbank, TUI im Fokus

Gorillas will französischen Essenslieferdienst Frichti übernehmen. Bundesnetzagentur erwägt Verzicht auf Mobilfunk-Auktion. Credit Suisse senkt Hannover Rück auf "Neutral" - Ziel 185 Euro. Haaland und Reus lassen BVB bei Hoffenheim jubeln - "überhaupt kein Zerwürfnis" zwischen BVB und Haaland. Hedgefonds Trian Partners will anscheinend mit Unilever-Beteiligung Druck machen.

Umfrage

Halten Sie es für richtig, dass die EZB an ihrer lockeren Geldpolitik festhält?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln